Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Pharmacokinetics

Background:

• Carbamazepine is an antiepileptic drug with a narrow therapeutic index.
• It is a non-ionizable, likely BCS Class 2 drug (low solubility, high permeability).
• Oral bioavailability is high (70-78%), indicating high permeability.

Purpose of the Study:

• To review literature on the applicability of BCS-based biowaivers for carbamazepine immediate-release (IR) solid oral dosage forms.
• To assess if carbamazepine meets criteria for BCS biowaiver eligibility.
• To explore alternative methods for predicting bioequivalence.

Main Methods:

• Literature review of studies on carbamazepine solubility, permeability, bioavailability, and therapeutic index.
• Analysis of BCS classification criteria in relation to carbamazepine properties.
• Evaluation of in vitro dissolution data and its correlation with in vivo bioequivalence.

Main Results:

• Carbamazepine is not highly soluble across physiological pH ranges.
• Despite low solubility, it exhibits high permeability and good oral bioavailability.
• Its narrow therapeutic index makes biowaivers unsuitable.
• USP dissolution conditions (900 mL water, 1% SLS, 75 rpm) distinguished bioinequivalent products in 90% of studies.

Conclusions:

• BCS-based biowaivers are not recommended for carbamazepine IR tablets due to its narrow therapeutic index and solubility challenges.
• Specific in vitro dissolution testing may serve as a surrogate for predicting bioequivalence.
• Further investigation into dissolution-based prediction models for carbamazepine is warranted.